{
  "items": [
    {
      "title": "Johnson & Johnson (NYSE:JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab",
      "description": "Johnson & Johnson (NYSE:JNJ) announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were significant events during the quarter. Additionally, the company's ongoing regulatory strides, including new designations for nipocalimab, offered a robust pipeline outlook. However, despite a 5% stock increase in the last quarter, JNJ's performance remained largely aligned with market...",
      "published_utc": "2025-04-10T02:09:48",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=d99df35d1c1095d4f157397e48a80b3da1f0861c50bc77923653aa8260ca723c",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "JNJ"
      ],
      "api_source": "finnhub_company",
      "id": 133841357,
      "datetime": 1744222188
    }
  ]
}